WuXi Biologics Receives South Korea GMP Certification for Bispecific Antibody Manufacturing

Key Takeaways

• WuXi Biologics received GMP certification from South Korea’s MFDS for three manufacturing facilities in Wuxi
• Certification enables end-to-end commercial manufacturing of bispecific antibody therapeutics for the South Korean market
• Expands WuXi Biologics’ regulatory footprint and commercial manufacturing capabilities in the Asia-Pacific region

---

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced on April 23, 2026, that three of its manufacturing facilities in Wuxi, China have received Good Manufacturing Practice (GMP) certification from South Korea’s Ministry of Food and Drug Safety (MFDS).

The certified facilities include Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug Product Packaging Center (DPPC). This regulatory milestone positions WuXi Biologics to provide comprehensive commercial manufacturing services for bispecific antibody therapeutics destined for the South Korean market.

Strategic Market Expansion

The MFDS GMP certification represents a significant expansion of WuXi Biologics’ regulatory compliance portfolio in the Asia-Pacific region. South Korea’s pharmaceutical market, valued at approximately $21 billion annually, presents substantial opportunities for bispecific antibody therapeutics, which represent one of the fastest-growing segments in oncology and immunology.

Bispecific antibodies, designed to simultaneously target two different antigens or epitopes, offer enhanced therapeutic potential compared to traditional monoclonal antibodies. These advanced therapeutics are increasingly important in cancer treatment, autoimmune disorders, and other complex diseases.

Manufacturing Capabilities Enhanced

With this certification, WuXi Biologics can now offer end-to-end commercial manufacturing services, from drug substance production through final packaging, specifically for products entering the South Korean market. This integrated approach provides pharmaceutical companies with streamlined regulatory pathways and reduced time-to-market for their bispecific antibody programs.

The certification also strengthens WuXi Biologics’ position as a preferred CRDMO partner for companies developing next-generation biologics targeting Asian markets. The company’s expanding regulatory footprint includes certifications from multiple international agencies, enabling global commercialization strategies for its partners’ therapeutic programs.

---

Frequently Asked Questions

What does this certification mean for bispecific antibody development?

The GMP certification enables WuXi Biologics to commercially manufacture bispecific antibodies for the South Korean market, providing pharmaceutical companies with a regulatory-compliant pathway to bring these advanced therapeutics to Korean patients.

Which facilities received the South Korea MFDS certification?

Three WuXi facilities received certification: Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug Product Packaging Center (DPPC), enabling complete end-to-end manufacturing capabilities.

How does this impact WuXi Biologics’ market position?

This certification expands WuXi Biologics’ regulatory footprint in Asia-Pacific, strengthening its position as a global CRDMO and enabling it to serve the growing South Korean pharmaceutical market worth approximately $21 billion annually.